definiens: within the meaning of The Private Securities Litigation Reform Act of1995, including statements regarding the timing of release of results from the phase III trial for XIAFLEX for the treatment ofPeyronie ’s disease ; Asahi Kasei Pharma ’s ability to develop, register for approval and commercialize XIAFLEX forDupuytren ’s contracture and Peyronie ’s disease in the licensed territory ; [COMPANY] ’s receipt of milestone payments androyalties from Asahi Kasei Pharma ; the benefits of the strategic alliance between [COMPANY] and Asahi Kasei Pharma ; the patentprotection for XIAFLEX ; the number of people suffering from Dupuytren ’s contracture and Peyronie ’s disease and products indevelopment for Peyronie ’s disease and Frozen Shoulder syndrome . All statements other than statements of historical factscontained in this release, including but not limited to, statements regarding future expectations, plans and prospects for theCompany, statements regarding forward - looking financial information and other statements containing the words and similarexpressions, as they relate to the Company, constitute forward - looking statements . Actual results may differ materially fromthose reflected in these forward - looking statements due to various factors, including further evaluation of clinical data, resultsof clinical trials, the performance of third - party service providers, decisions by regulatory authorities regarding whether orwhen to proceed to the next phase of clinical trials, general financial, economic, regulatory and political conditions affectingthe biotechnology and pharmaceutical industries and those discussed in the Company ’s Annual Report on Form 10 - K for theyear ended December 31, 2010 under the heading which is on file with the Securities and ExchangeCommission ( the ) and may be accessed electronically by means of the SEC ’s home page on the Internet athttp://www.sec.gov or by means of the Company ’s home page on ® ® CONFIDENTIALEXECUTION VERSION the Internet at http://www.auxilium.com under the heading There may be additional risks thatthe Company does not presently know or that the Company currently believes are immaterial which could also cause actualresults to differ from those contained in forward - looking statements . Given these risks and uncertainties, any or all of theforward - looking statements contained in this release may prove to be incorrect . Therefore, you should not rely on any suchfactors or forward - looking statements